BiotechTube
Caelus Health

Caelus Health

Amsterdam, Netherlands· Est.
caelushealth.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Caelus Health is a private, pre-revenue biotech firm pioneering microbiome-based therapeutics. The company's core asset is a precision probiotic strain, Anaerobutyricum soehngenii, which has undergone multiple clinical studies for metabolic health and is positioned for an initial commercial launch as a supplement for prediabetes and type 2 diabetes. Founded by award-winning scientists with research dating back to 2012, Caelus aims to translate deep microbiome science into accessible, evidence-based health solutions, with a longer-term vision to address autoimmune diseases and cancers.

Metabolic DiseasesInflammatory Diseases

Technology Platform

Precision probiotic platform focused on discovery, validation, and formulation of specific, proprietary bacterial strains with defined mechanisms of action for metabolic and inflammatory diseases.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

The global demand for scientifically-validated, non-pharmaceutical interventions for chronic metabolic diseases like diabetes is enormous and growing.
Success with its initial supplement could provide a revenue base and proof-of-concept to expand into adjacent, high-value therapeutic areas such as autoimmune disorders and oncology.

Risk Factors

Key risks include the challenge of differentiating a premium-priced, science-backed product in the crowded and often poorly regulated probiotic supplement market.
Furthermore, the company's long-term ambition to develop true therapeutics faces significant scientific, regulatory, and financial hurdles compared to the supplement pathway.

Competitive Landscape

Caelus operates in the highly competitive microbiome space, facing competition from large pharmaceutical companies (e.g., Seres Therapeutics, Vedanta Biosciences), consumer health giants with probiotic brands, and numerous other biotech startups. Its differentiation strategy is rooted in deep clinical validation and a 'precision' positioning for specific conditions.

More companies in Microbiome Therapeutics →More companies in Netherlands →